JPWO2022175255A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022175255A5 JPWO2022175255A5 JP2023549015A JP2023549015A JPWO2022175255A5 JP WO2022175255 A5 JPWO2022175255 A5 JP WO2022175255A5 JP 2023549015 A JP2023549015 A JP 2023549015A JP 2023549015 A JP2023549015 A JP 2023549015A JP WO2022175255 A5 JPWO2022175255 A5 JP WO2022175255A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- seq
- trispecific
- antibody
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163149921P | 2021-02-16 | 2021-02-16 | |
| US63/149,921 | 2021-02-16 | ||
| PCT/EP2022/053651 WO2022175255A2 (en) | 2021-02-16 | 2022-02-15 | Trispecific antibody targeting bcma, gprc5d, and cd3 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024507180A JP2024507180A (ja) | 2024-02-16 |
| JP2024507180A5 JP2024507180A5 (https=) | 2025-07-22 |
| JPWO2022175255A5 true JPWO2022175255A5 (https=) | 2025-07-22 |
Family
ID=80445956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023549015A Pending JP2024507180A (ja) | 2021-02-16 | 2022-02-15 | Ｂｃｍａ、ｇｐｒｃ５ｄ、及びｃｄ３を標的とする三重特異的抗体 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20220267438A1 (https=) |
| EP (1) | EP4294528A2 (https=) |
| JP (1) | JP2024507180A (https=) |
| KR (1) | KR20230146578A (https=) |
| CN (1) | CN117279953A (https=) |
| AR (1) | AR124882A1 (https=) |
| AU (1) | AU2022221884A1 (https=) |
| BR (1) | BR112023016121A2 (https=) |
| CA (1) | CA3211163A1 (https=) |
| CL (2) | CL2023002382A1 (https=) |
| CO (1) | CO2023011907A2 (https=) |
| CR (1) | CR20230398A (https=) |
| DO (1) | DOP2023000158A (https=) |
| EC (1) | ECSP23069904A (https=) |
| IL (1) | IL305144A (https=) |
| JO (1) | JOP20230192A1 (https=) |
| MX (1) | MX2023009566A (https=) |
| PE (1) | PE20241170A1 (https=) |
| TW (1) | TW202302636A (https=) |
| UY (1) | UY39634A (https=) |
| WO (1) | WO2022175255A2 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7303314B2 (ja) * | 2019-01-18 | 2023-07-04 | ヤンセン バイオテツク，インコーポレーテツド | Ｇｐｒｃ５ｄキメラ抗原受容体及びそれを発現する細胞 |
| TW202411253A (zh) * | 2022-06-06 | 2024-03-16 | 大陸商山東先聲生物製藥有限公司 | 靶向bcma、gprc5d和t細胞的多特異性抗體及其應用 |
| WO2024050797A1 (zh) * | 2022-09-09 | 2024-03-14 | 北京天广实生物技术股份有限公司 | 结合bcma、gprc5d和cd3的多特异性抗体及其用途 |
| TW202430211A (zh) * | 2022-10-10 | 2024-08-01 | 瑞士商赫孚孟拉羅股份公司 | Ｇｐｒｃ５ｄ ｔｃｂ及ｉｍｉｄ之組合療法 |
| CN117924485A (zh) * | 2022-10-25 | 2024-04-26 | 上海祥耀生物科技有限责任公司 | 一种抗gprc5d的多特异性抗体 |
| TW202434644A (zh) | 2023-02-07 | 2024-09-01 | 大陸商上海齊魯製藥研究中心有限公司 | 三特異性抗原結合分子及其應用 |
| WO2024168192A1 (en) * | 2023-02-10 | 2024-08-15 | Celgene Corporation | Assessment of bcma in biological samples |
| AU2024229501A1 (en) * | 2023-02-28 | 2025-10-16 | Janssen Biotech, Inc. | Compositions comprising a bispecific gprc5d/cd3 antibody |
| WO2024251154A1 (zh) * | 2023-06-06 | 2024-12-12 | 信达生物制药(苏州)有限公司 | 抗gprc5d/bcma/cd3三特异性抗体的制备及其用途 |
| WO2025043111A2 (en) * | 2023-08-23 | 2025-02-27 | Forte Subsidiary, Inc. | Multispecific immune cell engager |
| WO2025059362A1 (en) * | 2023-09-13 | 2025-03-20 | Juno Therapeutics, Inc. | Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025092742A1 (zh) * | 2023-10-30 | 2025-05-08 | 美国礼至生物医药股份有限公司 | 结合bcma的抗体以及包含其的多特异性抗体 |
| WO2025119153A1 (zh) * | 2023-12-04 | 2025-06-12 | 山东先声生物制药有限公司 | 一种多特异性抗体的组合物及其制备方法和应用 |
| WO2025134049A1 (en) | 2023-12-21 | 2025-06-26 | Janssen Biotech, Inc | Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of al amyloidosis |
| WO2025134050A1 (en) * | 2023-12-21 | 2025-06-26 | Janssen Biotech, Inc | Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of multiple myeloma |
| WO2025194478A1 (en) * | 2024-03-22 | 2025-09-25 | Biofront Ltd | Antibodies binding to cd3 and gprc5d, and uses thereof |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025250739A1 (en) | 2024-05-31 | 2025-12-04 | Janssen Biotech, Inc. | Chimeric antigen receptor with spacer domains derived from human igg |
| WO2025259877A1 (en) * | 2024-06-12 | 2025-12-18 | Evolveimmune Therapeutics, Inc. | Bispecific antibody fusion molecules targeting gprc5d and cd3 and methods of use thereof |
| WO2026078659A1 (en) * | 2024-10-11 | 2026-04-16 | Janssen Biotech, Inc. | Combination of trispecific antibody targeting bcma, gprc5d and cd3, and an anti-cd38 antibody for the treatment of multiple myeloma |
| WO2026078647A1 (en) | 2024-10-11 | 2026-04-16 | Janssen Biotech, Inc. | Combination of trispecific antibody targeting bcma, gprc5d and cd3, and pomalidomide for the treatment of multiple myeloma |
| US12545726B1 (en) | 2025-07-22 | 2026-02-10 | Integral Molecular, Inc. | Compositions and methods related to GPRC5D binding agents and variants thereof |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US20020142000A1 (en) | 1999-01-15 | 2002-10-03 | Digan Mary Ellen | Anti-CD3 immunotoxins and therapeutic uses therefor |
| WO2001024812A1 (en) | 1999-10-06 | 2001-04-12 | N.V. Nutricia | USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA |
| UA74798C2 (uk) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
| US20030012783A1 (en) | 2001-02-20 | 2003-01-16 | Wayne Kindsvogel | Antibodies that bind both BCMA and TACI |
| EP1789446A2 (en) | 2004-09-02 | 2007-05-30 | Genentech, Inc. | Heteromultimeric molecules |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| AU2006301492B2 (en) | 2005-10-11 | 2011-06-09 | Amgen Research (Munich) Gmbh | Compositions comprising cross-species-specific antibodies and uses thereof |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| WO2008119565A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific binding domain |
| WO2008119566A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific bispecific binders |
| RS53008B2 (sr) | 2007-04-03 | 2022-12-30 | Amgen Res Munich Gmbh | Interspecijski specifičan cd3-epsilon vezujući domen |
| PL2352763T5 (pl) | 2008-10-01 | 2023-01-30 | Amgen Research (Munich) Gmbh | Bispecyficzne przeciwciała jednołańcuchowe o specyficzności wobec antygenów docelowych o dużej masie cząsteczkowej |
| JP6126782B2 (ja) | 2008-10-01 | 2017-05-10 | アムゲン リサーチ （ミュンヘン） ゲーエムベーハー | 異種間特異的ｐｓｍａ×ｃｄ３二重特異性単鎖抗体 |
| CA2738568C (en) | 2008-10-01 | 2024-02-20 | Micromet Ag | Cross-species-specific single domain bispecific single chain antibody |
| BRPI0919881B1 (pt) | 2008-10-31 | 2021-09-08 | Centocor Ortho Biotech Inc | Proteína de arcabouço e seu método de geração, biblioteca e seu método de construção, molécula de ácido nucleico, vetor de ácido nucleico, célula hospedeira, composição, dispositivo médico e artigo de fabricação |
| BRPI1008532B1 (pt) | 2009-02-12 | 2021-12-14 | Janssen Biotech, Inc | Arcabouço de proteína isolada, método para construção de uma biblioteca de arcabouço de proteína isolada, molécula de ácido nucleico isolada, vetor de ácido nucleico isolado, célula hospedeira de bactéria ou fungo, composição, dispositivo médico e artigo de manufatura para uso farmacêutico ou de diagnóstico em seres humanos |
| EP2406284B9 (en) | 2009-03-10 | 2017-03-01 | Biogen MA Inc. | Anti-bcma antibodies |
| JP2012525149A (ja) | 2009-04-27 | 2012-10-22 | オンコメッド ファーマシューティカルズ インコーポレイテッド | ヘテロ多量体分子を作製するための方法 |
| DK2560993T3 (da) | 2010-04-20 | 2024-10-14 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof |
| PL2635607T3 (pl) | 2010-11-05 | 2020-05-18 | Zymeworks Inc. | Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC |
| CA2854233C (en) | 2011-11-04 | 2020-05-12 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
| EP3227324A4 (en) | 2014-12-05 | 2018-08-29 | Memorial Sloan Kettering Cancer Center | Antibodies targeting g-protein coupled receptor and methods of use |
| US10072088B2 (en) | 2015-08-17 | 2018-09-11 | Janssen Pharmaceutica, Nv | Anti-BCMA antibodies and uses thereof |
| TWI781108B (zh) | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途 |
| TW201837174A (zh) | 2017-02-07 | 2018-10-16 | 日商第一三共股份有限公司 | 抗ｇｐｒｃ５ｄ抗體及包含該抗體之分子 |
| CA3076099A1 (en) | 2017-09-22 | 2019-03-28 | Kite Pharma, Inc. | Linkers for chimeric antigen receptors |
| TWI829667B (zh) | 2018-02-09 | 2024-01-21 | 瑞士商赫孚孟拉羅股份公司 | 結合gprc5d之抗體 |
| US12012461B2 (en) * | 2018-05-16 | 2024-06-18 | Janssen Biotech, Inc. | Methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics |
| CA3099308A1 (en) * | 2018-05-21 | 2019-11-28 | Compass Therapeutics Llc | Compositions and methods for enhancing the killing of target cells by nk cells |
| US11603405B2 (en) * | 2018-05-24 | 2023-03-14 | Janssen Biotech, Inc. | Anti-CD3 antibodies and uses thereof |
| JOP20190116A1 (ar) | 2018-05-24 | 2019-11-24 | Janssen Biotech Inc | الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها |
| JP7303314B2 (ja) | 2019-01-18 | 2023-07-04 | ヤンセン バイオテツク，インコーポレーテツド | Ｇｐｒｃ５ｄキメラ抗原受容体及びそれを発現する細胞 |
| US20210284731A1 (en) * | 2020-03-13 | 2021-09-16 | Janssen Biotech, Inc. | Methods and materials for modulating an immune response |
| MX2023002948A (es) * | 2020-09-11 | 2023-05-22 | Janssen Biotech Inc | Métodos y composiciones para modular la inmunidad mediada por cadena beta. |
| KR20230084507A (ko) * | 2020-09-11 | 2023-06-13 | 얀센 바이오테크 인코포레이티드 | 다중-특이적 면역 표적화 분자 및 그의 용도 |
| CN112028996B (zh) * | 2020-10-30 | 2021-01-22 | 南京北恒生物科技有限公司 | 靶向bcma的单域抗体及其用途 |
-
2022
- 2022-02-15 IL IL305144A patent/IL305144A/en unknown
- 2022-02-15 EP EP22705543.1A patent/EP4294528A2/en active Pending
- 2022-02-15 MX MX2023009566A patent/MX2023009566A/es unknown
- 2022-02-15 US US17/672,123 patent/US20220267438A1/en active Pending
- 2022-02-15 WO PCT/EP2022/053651 patent/WO2022175255A2/en not_active Ceased
- 2022-02-15 CR CR20230398A patent/CR20230398A/es unknown
- 2022-02-15 JP JP2023549015A patent/JP2024507180A/ja active Pending
- 2022-02-15 CN CN202280028859.6A patent/CN117279953A/zh active Pending
- 2022-02-15 PE PE2023002364A patent/PE20241170A1/es unknown
- 2022-02-15 BR BR112023016121A patent/BR112023016121A2/pt unknown
- 2022-02-15 KR KR1020237031153A patent/KR20230146578A/ko active Pending
- 2022-02-15 AR ARP220100304A patent/AR124882A1/es unknown
- 2022-02-15 CA CA3211163A patent/CA3211163A1/en active Pending
- 2022-02-15 TW TW111105376A patent/TW202302636A/zh unknown
- 2022-02-15 AU AU2022221884A patent/AU2022221884A1/en active Pending
- 2022-02-16 UY UY0001039634A patent/UY39634A/es unknown
-
2023
- 2023-08-11 CL CL2023002382A patent/CL2023002382A1/es unknown
- 2023-08-11 DO DO2023000158A patent/DOP2023000158A/es unknown
- 2023-08-15 JO JOJO/P/2023/0192A patent/JOP20230192A1/ar unknown
- 2023-09-07 CO CONC2023/0011907A patent/CO2023011907A2/es unknown
- 2023-09-15 EC ECSENADI202369904A patent/ECSP23069904A/es unknown
-
2024
- 2024-08-22 CL CL2024002524A patent/CL2024002524A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2022175255A5 (https=) | ||
| US20240294660A1 (en) | ANTI-SIRPa ANTIBODY | |
| US20250171549A1 (en) | Anti-ccr8 antibodies and uses thereof | |
| AU2020213579B2 (en) | Anti-PD-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof | |
| JP2019536470A5 (https=) | ||
| CN110536903A (zh) | 抗ox40抗体及其用途 | |
| JP2018502062A (ja) | Ｃｄ３イプシロンおよびｂｃｍａに対する二特異性抗体 | |
| JP2020511947A5 (https=) | ||
| RU2018114523A (ru) | Анти-tigit антитела и способы применения | |
| RU2017121327A (ru) | Комбинированная терапия на основе активирующих т-клетки биспецифических антигенсвязывающих молекул против cd3 и фолатного рецептора 1 (folr1) и антагонистов, связывающихся с осью pd-1 | |
| RU2013146106A (ru) | Антитела против cd70 | |
| RU2019140602A (ru) | АНТИ-GARP-TGF-β-АНТИТЕЛА | |
| CA3139025A1 (en) | Tigit and pd-1/tigit-binding molecules | |
| JP2022111148A (ja) | 共刺激受容体およびチェックポイント受容体に連結する二重特異性免疫調節抗体 | |
| CN112480259B (zh) | 抗tnfr2抗体及其用途 | |
| WO2021167885A1 (en) | Cd137 binding molecules and uses thereof | |
| TW202104263A (zh) | 雙特異性CD123xCD3雙抗體在血液系統惡性腫瘤治療中的給藥方案 | |
| US20250197499A1 (en) | Novel formats of anti-CD28/sPD-1 fusion constructs | |
| CN121358492A (zh) | 用于治疗多发性骨髓瘤的方法 | |
| JPWO2023056252A5 (https=) | ||
| JPWO2022068809A5 (https=) | ||
| JPWO2023138551A5 (https=) | ||
| RU2024105343A (ru) | Белок, специфически связывающийся с pd-1, и его фармацевтическое применение | |
| RU2025121328A (ru) | МОЛЕКУЛА, СВЯЗЫВАЮЩАЯ TGFβ1, МОЛЕКУЛА, СВЯЗЫВАЮЩАЯ GARP-TGFβ1, И ИХ МЕДИЦИНСКОЕ ПРИМЕНЕНИЕ | |
| RU2025127414A (ru) | Антитела против 5т4 и их применения |